首页> 美国卫生研究院文献>Drug Delivery >Repaglinide-loaded nanostructured lipid carriers with different particle sizes for improving oral absorption: preparation characterization pharmacokinetics and in situ intestinal perfusion
【2h】

Repaglinide-loaded nanostructured lipid carriers with different particle sizes for improving oral absorption: preparation characterization pharmacokinetics and in situ intestinal perfusion

机译:具有不同颗粒尺寸的尾壁纳米结构脂质载体用于改善口服吸收:制备表征药代动力学和原位肠道灌注

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Repaglinide-loaded nanostructured lipid carriers (REP-NLCs) with different particle sizes were successfully designed and prepared to investigate the permeation and absorption ability by in situ single-pass intestinal perfusion (SPIP) study and pharmacokinetics. Both of the formulations prepared by solvent diffusion method exhibited a spherical shape under transmission electron microscopy (TEM) and similar zeta potential value of –11 mV. The particles size, encapsulation efficiency (EE), drug loading (DL) of REP-NLCs-Small and REP-NLCs-Large size preparations were about 79 nm and 325 nm, 96.83% and 98.60%, 4.41% and 3.05%, respectively. Besides, both REP-NLCs showed good colloidal stability and had no burst release phenomenon compared with REP-Sol. SPIP demonstrated the improved membrane permeability for NLCs compared with REP-Sol, especially NLCs-Small size preparation. The bioavailability increased sequentially in REP-Sol, REP-NLCs-Large, and REP-NLCs-Small, and the difference between each other was statistical significant. Our investigations demonstrate that NLCs with small particles size of 50–100 nm, such as 79 nm, are able to enhance absorption performance of a poorly soluble repaglinide compared with large particles size, such as 325 nm, by significantly improving the absorption in jejunum, and colon of rats and thus well improving oral bioavailability.
机译:成功设计了具有不同颗粒尺寸的尾流纳米结构的脂质载体(REP-NLC),并制备通过原位单通过肠灌注(SPIP)研究和药代动力学来研究渗透和吸收能力。通过溶剂扩散方法制备的两种制剂在透射电子显微镜(TEM)下表现出球形和-11mV的类似Zeta电位值。粒子尺寸,封装效率(EE),Rep-NLCS-Small和Rep-NLCS - 大尺寸制剂的药物负载(DL)为约79nm和325nm,96.83%和98.60%,4.41%和3.05% 。此外,两种rep-nlcs都表现出良好的胶体稳定性,与rep-sol相比没有爆发释放现象。与REP-SOL相比,尖尖表明了NLC的膜渗透性改善,特别是NLCS - 小尺寸制剂。在rep-sol,rep-nlcs-light和rep-nlcs-small中依次增加生物利用度,彼此之间的差异是统计显着的。我们的研究表明,具有50-100nm的小颗粒尺寸的NLC,例如79nm,通过显着改善Jejunum的吸收,可以增强差异差异较差的休闲术的吸收性能,如325nm,和大鼠的结肠,从而提高口服生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号